Home AsiaASEAN Asia Prefers China’s Sinovac in Coronavirus Fight

When a plane carrying Thailand’s first batch of COVID-19 vaccines from China’s Sinovac landed at an airport here on Wednesday, people waiting on the tarmac cheered and applauded.

“Thank you to the People’s Republic of China for delivering the first batch of vaccines this month and the following batches in the subsequent months,” said Thai Prime Minister Prayut Chan-o-cha, when he welcomed the vaccines’ arrival at the airport.

Prayut expressed his gratitude while a refrigerated container, with a banner reading “COVID-19 vaccines, returning smiles to Thailand” written in Thai, was lowered from the plane.

The Chinese vaccines would be distributed to 13 provinces of Thailand to prioritize health care workers and those most at risk, while more vaccine shipments are expected to arrive in March and April.

Thailand, known as the Land of Smiles, is heavily reliant on tourism but it recently has seen a drop in tourism due to COVID-19. The country welcomed about 40 million foreign tourists in 2019, but only 6.7 million last year.

It is widely expected that the COVID-19 vaccines will be a game-changer. Prayut hopes the vaccine would contribute to the recovery of the tourism sector through easing restrictive measures, such as exempting vaccinated tourists from the two-week mandatory quarantine.

The arrival of the Sinovac vaccines marks a significant move to jumpstart the vaccination process in Thailand and thus catch up with other member countries of the Association of Southeast Asian Nations (ASEAN), said Tang Zhimin, director of China ASEAN Studies at the Bangkok-based Panyapiwat Institute of Management.

Elsewhere in the ASEAN region, where COVID-19 has claimed more than 50,000 lives from over 2.4 million cases, countries are placing their trust in China as they have ordered, received or approved the emergency use of Chinese vaccines.

Among the biggest takers of the Chinese vaccines is Indonesia, which has ordered a large number of doses of the Sinovac vaccine.

“We should ensure the quality, safety and effectiveness. That’s the first one. Then the second one is, of course, they have to be listed in the WHO (World Health Organization) recommendation,” said Siti Nadia Tarmizi, the Indonesian government’s spokesperson for COVID-19 vaccination.

In a livestream, Indonesian President Joko Widodo on Jan. 13 rolled up his sleeves to receive his first shot of the Sinovac vaccine, kicking off the nation’s mass inoculation campaign.

The massive vaccination program would help Indonesia achieve herd immunity after 181.5 million people, or around two thirds of the country’s population, are inoculated within 15 months, said Indonesia’s Deputy Minister of Health Dante Saksono.

The largest economy in Southeast Asia is pinning its hope on the mass vaccination drive to curb its soaring cases, which have exceeded 1.3 million, and revitalize its virus-hit economy.

On Saturday, Malaysia also received its first delivery of the Sinovac vaccine, days after the country kicked off its inoculation program, which aims to inoculate at least 80 percent of the country’s total population.

Viruses do not respect borders and only by cooperating in the spirit of solidarity can the international community overcome the pandemic, said Chinese Ambassador to Malaysia Ouyang Yujing.

As COVID-19 is still raging and countries around the world are scrambling to obtain vaccines, which are in short supply, China has promised to make Chinese COVID-19 vaccines a global public good.

You may also like

logo-white

Your Trusted Source for Capital Markets & Related News

© 2024 LiveTradingNews.com – For The Traders, By The Traders – All Right Reserved.

The information contained on this website shall not be construed as (i) an offer to purchase or sell, or the solicitation of an offer to purchase or sell, any securities or services, (ii) investment, legal, business or tax advice or an offer to provide such advice, or (iii) a basis for making any investment decision. An offering may only be made upon a qualified investor’s receipt not via this website of formal materials from the Knightsbridge an offering memorandum and subscription documentation (“offering materials”). In the case of any inconsistency between the information on this website and any such offering materials, the offering materials shall control. Securities shall not be offered or sold in any jurisdiction in which such offer or sale would be unlawful unless the requirements of the applicable laws of such jurisdiction have been satisfied. Any decision to invest in securities must be based solely upon the information set forth in the applicable offering materials, which should be read carefully by qualified investors prior to investing. An investment with Knightsbridge is not suitable or desirable for all investors; investors may lose all or a portion of the capital invested. Investors may be required to bear the financial risks of an investment for an indefinite period of time. Qualified investors are urged to consult with their own legal, financial and tax advisors before making any investment. Knightsbridge is a private investment firm that offers investment services to Qualified Investors, Members and Institutions ONLY. Qualified Investors are defined as individuals who have met those Qualifications in the relevant jurisdictions. Members are defined as individuals who have been accepted into the Knightsbridge membership program. Institutions are defined as entities such as banks, pension funds, and hedge funds. If you are not a Qualified Investor, Member or Institution, you are not eligible to invest with Knightsbridge. All investments involve risk, and there is no guarantee of profit. You may lose some or all of your investment. Past performance is not indicative of future results. Knightsbridge is not a registered investment advisor, and this disclaimer should not be construed as investment advice. Please consult with a qualified financial advisor before making any investment decisions. By accessing this website, you agree to the terms of this disclaimer. Thank you for your interest in Knightsbridge.